- Home
- SLNO
as 07-26-2024 4:00pm EST
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 1.5B | IPO Year: | 2014 |
| Target Price: | $60.33 | AVG Volume (30 days): | 530.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.69 - $53.82 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Soleno Therapeutics Inc. (SLNO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Jul 1 '24 | Sell | $41.63 | 15,058 | $626,795.27 | 133,534 | SEC Form 4 |
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Jul 1 '24 | Sell | $41.22 | 4,198 | $173,048.70 | 148,592 | SEC Form 4 |
| Hirano Patricia C | SLNO | SEE REMARKS | Jul 1 '24 | Sell | $41.63 | 1,697 | $70,638.30 | 48,754 | SEC Form 4 |
| Hirano Patricia C | SLNO | SEE REMARKS | Jul 1 '24 | Sell | $41.22 | 473 | $19,497.86 | 50,451 | SEC Form 4 |
| Yen Kristen | SLNO | SEE REMARKS | Jul 1 '24 | Sell | $41.63 | 1,697 | $70,638.30 | 21,252 | SEC Form 4 |
| Yen Kristen | SLNO | SEE REMARKS | Jul 1 '24 | Sell | $41.22 | 473 | $19,497.86 | 22,949 | SEC Form 4 |
| Vivo Opportunity, LLC | SLNO | 10% Owner | Apr 29 '24 | Sell | $47.80 | 750,000 | $35,850,000.00 | 7,668,093 | SEC Form 4 |
| Vivo Opportunity, LLC | SLNO | 10% Owner | Apr 29 '24 | Sell | $45.13 | 351,242 | $15,851,551.46 | 7,316,851 | SEC Form 4 |
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Apr 1 '24 | Sell | $41.67 | 7,597 | $316,544.96 | 152,790 | SEC Form 4 |
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Apr 1 '24 | Sell | $41.12 | 11,383 | $468,099.69 | 160,387 | SEC Form 4 |
| Yen Kristen | SLNO | SEE REMARKS | Apr 1 '24 | Sell | $41.12 | 1,330 | $54,693.19 | 24,310 | SEC Form 4 |
| Yen Kristen | SLNO | SEE REMARKS | Apr 1 '24 | Sell | $41.67 | 888 | $37,000.38 | 23,422 | SEC Form 4 |
| Hirano Patricia C | SLNO | SEE REMARKS | Apr 1 '24 | Sell | $41.12 | 1,330 | $54,693.19 | 41,812 | SEC Form 4 |
| Hirano Patricia C | SLNO | SEE REMARKS | Apr 1 '24 | Sell | $41.67 | 888 | $37,000.38 | 50,924 | SEC Form 4 |
| Mackaness James H | SLNO | CHIEF FINANCIAL OFFICER | Apr 1 '24 | Sell | $41.12 | 3,104 | $127,644.86 | 65,024 | SEC Form 4 |
| Mackaness James H | SLNO | CHIEF FINANCIAL OFFICER | Apr 1 '24 | Sell | $41.67 | 2,071 | $86,292.56 | 62,953 | SEC Form 4 |
| Hirano Patricia C | SLNO | SEE REMARKS | Jan 25 '24 | Sell | $48.30 | 832 | $40,185.60 | 43,142 | SEC Form 4 |
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Jan 25 '24 | Sell | $48.30 | 2,527 | $122,054.10 | 171,770 | SEC Form 4 |
| Yen Kristen | SLNO | SEE REMARKS | Jan 25 '24 | Sell | $48.30 | 397 | $19,175.10 | 25,640 | SEC Form 4 |
| Yen Kristen | SLNO | See Remarks | Dec 12 '23 | Sell | $36.64 | 3,629 | $132,967.29 | 18,321 | SEC Form 4 |
| Yen Kristen | SLNO | See Remarks | Dec 12 '23 | Sell | $37.02 | 16,284 | $602,906.96 | 2,037 | SEC Form 4 |
| Yen Kristen | SLNO | See Remarks | Dec 12 '23 | Sell | $37.76 | 17,916 | $676,556.53 | 2,037 | SEC Form 4 |
| Anish Bhatnagar | SLNO | Chief Executive Officer | Dec 11 '23 | Sell | $35.26 | 51,205 | $1,805,478.06 | 66,500 | SEC Form 4 |
| Anish Bhatnagar | SLNO | Chief Executive Officer | Dec 11 '23 | Sell | $36.00 | 35,272 | $1,269,728.51 | 31,228 | SEC Form 4 |
| Anish Bhatnagar | SLNO | Chief Executive Officer | Dec 11 '23 | Sell | $37.01 | 6,931 | $256,494.82 | 24,297 | SEC Form 4 |
Latest Soleno Therapeutics Inc. News
SLNO Breaking Stock News: Dive into SLNO Ticker-Specific Updates for Smart Investing
TipRanks
9 days ago
These Stock Winners Are ‘Strong Buys’ With More Room Left to Run
MT Newswires
a month ago
Soleno Therapeutics Submits New Drug Application to FDA for Prader-Willi Syndrome Treatment
GlobeNewswire
a month ago
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
GlobeNewswire
a month ago
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
2 months ago
Soleno Therapeutics to Join Russell 3000 Index
GlobeNewswire
2 months ago
Soleno Therapeutics Set to Join Russell 3000® Index
GlobeNewswire
2 months ago
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
GlobeNewswire
2 months ago
Soleno Therapeutics to Participate in Upcoming Investor Conferences
Compare SLNO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLNO Soleno Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.